Thus, rosiglitazone (as a Smad/TGFβ antagonist) and Gleevec (as a PDGFRβ inhibitor) act at different steps in a linear sequence of events (Figure 5) that result in a Marfan-like syndrome and culminate in extensive atherosclerosis in smLRP− artery walls. The gene discussed is PDGFRB; the disease is atherosclerosis.